Alovudine (MIV-310)

Therapy Area
An NRTI for treatment of patients infected with multiresistant HIV.
Competitive Edge
Striking activity against multiresistant HIV in phase II studies, including in very low doses.
Licensee
Presidio Pharmaceuticals

Last Modified: 05/09/2008